Published in Arthritis Care Res (Hoboken) on July 01, 2010
Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis (2013) 1.32
The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis. BMC Musculoskelet Disord (2013) 1.22
Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers. Ann Rheum Dis (2013) 1.07
Measuring disease activity in psoriatic arthritis. Int J Rheumatol (2012) 0.90
Hepatic steatosis, carotid plaques and achieving MDA in psoriatic arthritis patients starting TNF-α blockers treatment: a prospective study. Arthritis Res Ther (2012) 0.90
Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled Study. Arthritis Care Res (Hoboken) (2016) 0.86
Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. Nat Rev Rheumatol (2016) 0.75
Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study. Arthritis Res Ther (2017) 0.75
On Modelling Minimal Disease Activity. Arthritis Care Res (Hoboken) (2016) 0.75
Real-world validation of the minimal disease activity index in psoriatic arthritis: an analysis from a prospective, observational, biological treatment registry. BMJ Open (2017) 0.75
[Psoriatric arthritis - a permanent challenge for rheumatologists and patients: part 2: imaging diagnostics, classification and therapy]. Z Rheumatol (2011) 0.75
[Psoriatic arthritis : a permanent challenge for rheumatologists and patients--Part 1: epidemiology, pathogenesis and clinical course]. Z Rheumatol (2011) 0.75
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet (2012) 4.13
Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. Arthritis Rheum (2013) 4.02
Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol (2005) 3.31
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol (2005) 3.22
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst (2005) 3.08
Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol (2005) 3.04
Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet (2013) 2.87
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum (2005) 2.80
Genome-wide association analysis identifies three psoriasis susceptibility loci. Nat Genet (2010) 2.76
Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nat Genet (2010) 2.66
Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer (2007) 2.55
Development and assessment of users' satisfaction with the systemic lupus erythematosus disease activity index 2000 responder index-50 website. J Rheumatol (2012) 2.48
Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J Rheumatol (2008) 2.11
Repair of radiographic joint damage following treatment with etanercept in psoriatic arthritis is demonstrable by 3 radiographic methods. J Rheumatol (2011) 2.07
The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum (2010) 2.06
Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum (2008) 2.06
Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Am J Hum Genet (2012) 1.88
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis (2014) 1.88
Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort. J Rheumatol (2007) 1.73
Is there an advantage over SF-36 with a quality of life measure that is specific to systemic lupus erythematosus? J Rheumatol (2011) 1.72
Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer (2010) 1.71
Persistent proteinuria and dyslipidemia increase the risk of progressive chronic kidney disease in lupus erythematosus. Kidney Int (2011) 1.63
Anti-dsDNA antibody testing by Farr and ELISA techniques is not equivalent. J Rheumatol (2006) 1.62
Consensus on a core set of domains for psoriatic arthritis. J Rheumatol (2007) 1.60
Risk factors for development of coronary artery disease in women with systemic lupus erythematosus. J Rheumatol (2009) 1.58
Serum autoantibodies that bind citrullinated fibrinogen are frequently found in patients with rheumatoid arthritis. J Rheumatol (2006) 1.54
Axial psoriatic arthritis: update on a longterm prospective study. J Rheumatol (2009) 1.53
Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol (2011) 1.52
Diffuse idiopathic skeletal hyperostosis in psoriatic arthritis. J Rheumatol (2013) 1.51
Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol (2013) 1.50
Effect of psoriatic arthritis according to the affected categories of the international classification of functioning, disability and health. J Rheumatol (2010) 1.46
Hiding in plain sight: what Koppel et al. tell us about healthcare IT. J Biomed Inform (2005) 1.44
Qualifying unmet needs and improving standards of care in psoriatic arthritis. Arthritis Care Res (Hoboken) (2014) 1.43
Time to recovery from proteinuria in patients with lupus nephritis receiving standard treatment. J Rheumatol (2014) 1.42
Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum (2012) 1.40
Association of interleukin-23 receptor variants with ankylosing spondylitis. Arthritis Rheum (2008) 1.38
Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum (2003) 1.38
Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res (Hoboken) (2011) 1.35
Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev (2008) 1.32
Predictors for radiological damage in psoriatic arthritis: results from a single centre. Ann Rheum Dis (2006) 1.28
Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. Rheumatology (Oxford) (2011) 1.26
A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood (2008) 1.25
Shear-induced disulfide bond formation regulates adhesion activity of von Willebrand factor. J Biol Chem (2007) 1.24
Peripheral neuropathy in patients with systemic lupus erythematosus. Semin Arthritis Rheum (2011) 1.23
A conditional Markov model for clustered progressive multistate processes under incomplete observation. Biometrics (2004) 1.18
Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. J Rheumatol (2005) 1.17
A multicenter pilot-randomized controlled trial of the feasibility of an augmented red blood cell transfusion strategy for patients treated with induction chemotherapy for acute leukemia or stem cell transplantation. Transfusion (2007) 1.17
The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis (2012) 1.15
Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus. J Rheumatol (2003) 1.14
Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum (2009) 1.13
Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. J Rheumatol (2006) 1.13
Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis. Ann Rheum Dis (2007) 1.12
International spondyloarthritis interobserver reliability exercise--the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. J Rheumatol (2007) 1.11
The effect of pregnancy on lupus nephritis. Arthritis Rheum (2004) 1.10
TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis. J Invest Dermatol (2011) 1.10
Bleeding during critical illness: a prospective cohort study using a new measurement tool. Clin Invest Med (2007) 1.10
Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. Arthritis Rheum (2007) 1.09
Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am (2005) 1.09
Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. Rheumatology (Oxford) (2010) 1.08
Systemic lupus erythematosus disease activity index 2000 responder index-50 website. J Rheumatol (2013) 1.07
Antihomocitrullinated fibrinogen antibodies are specific to rheumatoid arthritis and frequently bind citrullinated proteins/peptides. J Rheumatol (2014) 1.07
Association of interleukin 23 receptor variants with psoriatic arthritis. J Rheumatol (2009) 1.06
Human leucocyte antigen risk alleles for psoriatic arthritis among patients with psoriasis. Ann Rheum Dis (2011) 1.06
Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol (2008) 1.05
A longitudinal study of the effect of disease activity and clinical damage on physical function over the course of psoriatic arthritis: Does the effect change over time? Arthritis Rheum (2007) 1.05
Prediction of falls using a risk assessment tool in the acute care setting. BMC Med (2004) 1.05
Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. Ann Rheum Dis (2012) 1.05
Description and prediction of physical functional disability in psoriatic arthritis: a longitudinal analysis using a Markov model approach. Arthritis Rheum (2005) 1.04
International spondyloarthritis interobserver reliability exercise--the INSPIRE study: I. Assessment of spinal measures. J Rheumatol (2007) 1.04
Genome-wide meta-analysis of psoriatic arthritis identifies susceptibility locus at REL. J Invest Dermatol (2011) 1.04
Quality of life over time in patients with systemic lupus erythematosus. Arthritis Rheum (2008) 1.03
Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann Rheum Dis (2013) 1.03
International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. Arthritis Rheum (2009) 1.02
Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis (2012) 1.02
Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease? Ann Rheum Dis (2011) 1.02
Fluorescence lifetime endoscopy using TCSPC for the measurement of FRET in live cells. Opt Express (2010) 1.01
Consensus on the utility of bone markers in the malignant bone disease setting. Crit Rev Oncol Hematol (2011) 1.01
Prevalence of malignancy in psoriatic arthritis. Arthritis Rheum (2008) 1.01
Psoriatic arthritis screening tools. J Rheumatol (2008) 1.00
Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria. J Rheumatol (2009) 1.00
Differences in body mass index among individuals with PsA, psoriasis, RA and the general population. Rheumatology (Oxford) (2011) 1.00
The 1000 Canadian faces of lupus: determinants of disease outcome in a large multiethnic cohort. J Rheumatol (2009) 1.00
Improved survival in psoriatic arthritis with calendar time. Arthritis Rheum (2007) 1.00
Genetics of psoriasis and psoriatic arthritis: update and future direction. J Rheumatol (2008) 0.98
Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency. J Crit Care (2005) 0.98
The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. J Rheumatol (2013) 0.97
Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis. J Rheumatol (2010) 0.97